130 related articles for article (PubMed ID: 17596200)
1. Response to Pokharna and Kanna: initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Garber A
Diabetes Obes Metab; 2008 May; 10(5):436-7. PubMed ID: 17596200
[No Abstract] [Full Text] [Related]
2. Letter to the editor in reference to article titled: Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
Pokharna H; Kanna B
Diabetes Obes Metab; 2007 Nov; 9(6):914. PubMed ID: 17394564
[No Abstract] [Full Text] [Related]
3. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
[TBL] [Abstract][Full Text] [Related]
4. [Blood sugar inspite of maximal metformin dosage. New fixed combination forces HbA1c down].
MMW Fortschr Med; 2003 Dec; 145(50):54. PubMed ID: 14963975
[No Abstract] [Full Text] [Related]
5. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
6. [Rosiglitazone: clinical data].
Blickle JF
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S27-33. PubMed ID: 12037505
[No Abstract] [Full Text] [Related]
7. [Rosiglitazone-metformin fixed dose combination for treatment of type 2 diabetes].
Sauvanet JP
Presse Med; 2004 Dec; 33(22):1617. PubMed ID: 15688519
[No Abstract] [Full Text] [Related]
8. Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.
Bailey CJ; Day C
Int J Clin Pract; 2004 Sep; 58(9):867-76. PubMed ID: 15529521
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.
Del Prato S; Volpe L
Expert Opin Pharmacother; 2004 Jun; 5(6):1411-22. PubMed ID: 15163284
[TBL] [Abstract][Full Text] [Related]
10. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulphonylurea agent: response to Roy et al.
De P
Diabetes Care; 2004 Dec; 27(12):3027; author reply 3027-8. PubMed ID: 15562243
[No Abstract] [Full Text] [Related]
11. Rosiglitazone/Metformin.
Wellington K
Drugs; 2005; 65(11):1581-92; discussion 1593-4. PubMed ID: 16033298
[TBL] [Abstract][Full Text] [Related]
12. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients: response to Poulsen et al.
Mikhail N
Diabetes Care; 2004 Jul; 27(7):1846-7; author reply 1847-8. PubMed ID: 15220287
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of a combination of metformin and rosiglitaone in patients with type 2 diabetes mellitus--a postmarketing study.
Ballary C; Desai A
J Indian Med Assoc; 2003 Feb; 101(2):113-4, 123. PubMed ID: 12841496
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
[TBL] [Abstract][Full Text] [Related]
15. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and a sulfonylurea agent: a systematic evaluation of triple oral therapy in a minority population.
Roy R; Navar M; Palomeno G; Davidson MB
Diabetes Care; 2004 Jul; 27(7):1741-2. PubMed ID: 15220256
[No Abstract] [Full Text] [Related]
16. Postmarketing pharmacovigilance of adverse drug reactions: the case of rosiglitazone in Mexico.
Reyes-Morales H; Mino-León D; Doubova SV; Flores-Hernández S
Int J Clin Pharmacol Ther; 2012 Jan; 50(1):1-9. PubMed ID: 22192639
[TBL] [Abstract][Full Text] [Related]
17. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G
Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162
[TBL] [Abstract][Full Text] [Related]
18. Complementary mode of action of rosiglitazone and metformin in a single tablet for the treatment of diabetes mellitus type 2.
Petersen KU
Arzneimittelforschung; 2004; 54(1):20-30. PubMed ID: 14979605
[No Abstract] [Full Text] [Related]
19. Re: "Effect of metformin and rosiglitazone in a prepubertal boy with Alström syndrome", Sinha SK et al., JPEM 2007; 20: 1045-1052.
Atabek ME
J Pediatr Endocrinol Metab; 2008 Jan; 21(1):100; author reply 100-1. PubMed ID: 18404981
[No Abstract] [Full Text] [Related]
20. Thiazolidinedione derivatives in type 2 diabetes mellitus.
Tack CJ; Smits P
Neth J Med; 2006 Jun; 64(6):166-74. PubMed ID: 16788214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
